Johnson & Johnson (NYSE:JNJ) Position Increased by Center for Financial Planning Inc.

Center for Financial Planning Inc. increased its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 3.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,113 shares of the company’s stock after purchasing an additional 442 shares during the period. Johnson & Johnson accounts for 0.5% of Center for Financial Planning Inc.’s portfolio, making the stock its 17th largest position. Center for Financial Planning Inc.’s holdings in Johnson & Johnson were worth $2,501,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Norges Bank bought a new stake in Johnson & Johnson during the 4th quarter valued at $4,172,929,000. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after acquiring an additional 4,982,885 shares in the last quarter. GQG Partners LLC raised its stake in Johnson & Johnson by 1,109.4% during the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after acquiring an additional 3,627,424 shares in the last quarter. State Street Corp raised its stake in Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after buying an additional 1,084,834 shares in the last quarter. Institutional investors own 68.78% of the company’s stock.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.6 %

Shares of JNJ opened at $172.92 on Wednesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $455.02 billion, a price-to-earnings ratio of 25.17, a P/E/G ratio of 3.32 and a beta of 0.59. The stock’s 50-day moving average price is $175.67 and its 200 day moving average price is $174.49.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period in the prior year, the company posted $2.48 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Analyst Ratings Changes

A number of brokerages recently issued reports on JNJ. Citigroup decreased their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Raymond James boosted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Finally, Morgan Stanley boosted their price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.